|
|
Ars Pharmaceuticals Inc (NASDAQ: SPRY) |
|
|
|
|
|
Ars Pharmaceuticals Inc's Suppliers Performance
SPRY's Supply Chain
|
Select the Relationship:
|
|
Select the Category:
|
|
Ars Pharmaceuticals Inc's Comment on Supply Chain
SPRY's vs. Suppliers, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
| COMPANY NAME |
MARKET CAP |
REVENUES |
INCOME |
EMPLOYEES |
|
Ars Pharmaceuticals Inc
|
1,421.64 |
0.00 |
8.00 |
31 |
| SUBTOTAL |
0.00 |
0.00 |
0.00 |
- |
News about
Ars Pharmaceuticals Inc Contracts
|
The Innovative Breakthrough of neffy: Redefining Epinephrine Delivery for Anaphylaxis The rapid onset of anaphylaxis is a potentially life-threatening reaction in susceptible individuals, necessitating immediate administration of epinephrine. Traditionally, this has been achieved by intramuscular injection via autoinjectors. However, the inherent inconvenience and needle-fear associated with this delivery method present significant barriers to timely administration. ARS Pharmaceuticals has recently pioneered a revolutionary approach with their development of neffy, the first and only needle-free epinephrine nasal spray approved by the U.S. Food and Drug Administration (FDA). Historical ContextEpinephrine ha...
|
:This article delves into the significant events surrounding ARS Pharmaceuticals efforts to market their revolutionary product, neffy, an epinephrine nasal spray developed for the potential treatment of severe allergic reactions. Attention is specifically drawn to the company?s response to the European Medicines Agency s Committee for Medicinal Products for Human Use (EMA s CHMP), and the licensing agreement with CSL Seqirus to commercialize neffy in Australia and New Zealand.Keywords: ARS Pharmaceuticals, Epinephrine Nasal Spray, Neffy, CSL Seqirus, EMA s CHMP, Severe Allergic ReactionsARS Pharmaceuticals is making monumental strides in the pharmaceutical industry with its unique product, neffy , an epine...
|
Chronic spontaneous urticaria is a distressing skin disorder characterized by recurring episodes of itchy hives and angioedema. Unfortunately, a significant number of patients with this condition do not respond adequately to conventional antihistamine therapy. In a recent phase 2 clinical study, ARS Pharmaceuticals, Inc. announced encouraging results for their investigational drug, Neffy (epinephrine nasal spray). This article will delve into the study s findings, analyzing the potential of Neffy to revolutionize the management of chronic spontaneous urticaria and improve the quality of life for affected patients.Overview of the Study:The phase 2 clinical trial conducted by ARS Pharmaceuticals evaluated the ...
|
|
